Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays

Kahre, Elisabeth; Galow, Lukas; Unrath, Manja; Haag, Luise; Blankenburg, Judith; Dalpke, Alexander H.; Lück, Christian; Berner, Reinhard; Armann, Jakob

doi:10.1038/s41598-021-94453-5

Cited by 8 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 We estimated the average time from seroconversion to seroreversion to have a mean of 229.7 days (7.6 months) and SD 105.3 days by fitting a Weibull distribution, using a weighted least squares method, to published data on the duration of seropositivity measured by the Abbott ARCHITECT SARS-CoV-2 anti-nucleocapsid immunoglobulin G immunoassay (Supporting Information: Figure S2). 10,11 This assay was used in the Nationwide Commercial Lab Seroprevalence study in Michigan. 4 Daily MDSS cases were multiplied by the age-and time-specific case adjustment factors and their 95% CrI to estimate a range of total infections.…”

mentioning

confidence: 99%

“…Detection improved to six infections per report in the summer of 2020 before gradually worsening to 25 infections per report after June 2021. In contrast, infections among adults were much more likely to be detected throughout the pandemic, but under-detection increased over time with the highest numbers of infections per report(8)(9)(10)(11)(12)(13)(14) after June 2021. Accounting for under-detection, we estimate the cumulative incidence of infection in Michigan reached 75% by mid-November 2021.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The variant‐specific burden of SARS‐CoV‐2 in Michigan: March 2020 through November 2021

Petrie

Eisenberg

Lauring

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Accurate estimates of the total burden of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are needed to inform policy, planning, and response. We sought to quantify SARS‐CoV‐2 cases, hospitalizations, and deaths by age in Michigan. Coronavirus disease 2019 cases reported to the Michigan Disease Surveillance System were multiplied by age and time‐specific adjustment factors to correct for under‐detection. Adjustment factors were estimated in a model fit to incidence data and seroprevalence estimates. Age‐specific incidence of SARS‐CoV‐2 hospitalization, death, vaccination, and variant proportions were estimated from publicly available data. We estimated substantial under‐detection of infection that varied by age and time. Accounting for under‐detection, we estimate the cumulative incidence of infection in Michigan reached 75% by mid‐November 2021, and over 87% of Michigan residents were estimated to have had ≥1 vaccination dose and/or previous infection. Comparing pandemic waves, the relative burden among children increased over time. In general, the proportion of cases who were hospitalized or who died decreased over time. Our results highlight the ongoing risk of periods of high SARS‐CoV‐2 incidence despite widespread prior infection and vaccination. This underscores the need for long‐term planning for surveillance, vaccination, and other mitigation measures amidst continued response to the acute pandemic.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

The variant‐specific burden of SARS‐CoV‐2 in Michigan: March 2020 through November 2021

Petrie

Eisenberg

Lauring

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…However, it is important to mention, that 20.8% of the seronegative participants also reported symptoms ≥ 12 weeks after COVID-19 within their household. Even though there is no seroconversion in about 10% of people after a SARS-CoV-2 infection 26 , 27 , these results show that there is a certain background incidence of medical conditions that is not related to the virus infection. Part of it most likely represents a baseline level of non-specific symptoms within our population which might be elevated due to the restrictions during the pandemic.…”

Section: Discussionmentioning

confidence: 80%

Lower SARS-CoV-2 household transmission in children and adolescents compared to adults

Schumm

Blankenburg

Kahre

et al. 2022

Sci Rep

View full text Add to dashboard Cite

In the COVID-19 pandemic, children were considered to play a major role in SARS-CoV-2 transmission similar to influenza. Thus, mitigation measures have been focused on children, impacting their everyday life severely. Despite this, infectivity in this age group regarding SARS-CoV-2 is not yet clarified. We performed a serology study in households with confirmed SARS-CoV-2 infection to evaluate virus transmission with focus on children and adolescents. Between January and July 2021, 341 minors and 650 adults from 300 households with a confirmed index case participated in the FamilyCoviDD19-study including serological assessment for SARS-CoV-2 antibodies and a questionnaire on demographics, recent and ongoing symptoms, hygiene measures and comorbidities. 45 (16.3%) of all index cases were < 18 years old. Thereof, 55.6% reported COVID-19 associated symptoms, while nearly all adult index cases were symptomatic (94.8%). There was significantly less virus transmission by children and adolescents compared to adult index cases with a secondary attack rate of 0.29 vs. 0.54. With the caveat that the results do not necessarily apply to the Delta and Omicron variants, we conclude that children and adolescents are less susceptible for SARS-CoV-2 infection, more frequently show an asymptomatic course of disease and are less infective than adults.

show abstract

“…the duration a case would be detectable by serology) followed a Weibull distribution with mean 229.7 days (7.6 months) and SD 105.3 days. These parameters were estimated by fitting a Weibull distribution, using a weighted least squares method, to published data on the duration of seropositivity as measured by the Abbott ARCHITECT SARS-CoV-2 IgG immunoassay targeting the nucleocapsid protein (Supplemental Figure 2) 10,11 . This assay was used in the CDC’s Nationwide Commercial Lab Seroprevalence study to estimate seropositivity in Michigan 4 .…”

Section: Methodsmentioning

confidence: 99%

Variant-specific burden of SARS-CoV-2 in Michigan: March 2020 through November 2021

Petrie

Eisenberg

Lauring

et al. 2022

Preprint

View full text Add to dashboard Cite

Accurate estimates of total burden of SARS-CoV-2 are needed to inform policy, planning and response. We sought to quantify SARS-CoV-2 cases, hospitalizations, and deaths by age in Michigan. COVID-19 cases reported to the Michigan Disease Surveillance System were multiplied by age and time-specific adjustment factors to correct for under-detection. Adjustment factors were estimated in a model fit to incidence data and seroprevalence estimates. Age-specific incidence of SARS-CoV-2 hospitalization, death, and vaccination, and variant proportions were estimated from publicly available data. We estimated substantial under-detection of infection that varied by age and time. Accounting for under-detection, we estimate cumulative incidence of infection in Michigan reached 75% by mid-November 2021, and over 87% of Michigan residents were estimated to have had ≥1 vaccination dose and/or previous infection. Comparing pandemic waves, the relative burden among children increased over time. Adults ≥80 years were more likely to be hospitalized or die if infected in fall 2020 than if infected during later waves. Our results highlight the ongoing risk of periods of high SARS-CoV-2 incidence despite widespread prior infection and vaccination. This underscores the need for long-term planning for surveillance, vaccination, and other mitigation measures amidst continued response to the acute pandemic.

show abstract

Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays

Cited by 8 publications

References 8 publications

The variant‐specific burden of SARS‐CoV‐2 in Michigan: March 2020 through November 2021

The variant‐specific burden of SARS‐CoV‐2 in Michigan: March 2020 through November 2021

Lower SARS-CoV-2 household transmission in children and adolescents compared to adults

Variant-specific burden of SARS-CoV-2 in Michigan: March 2020 through November 2021

Contact Info

Product

Resources

About